[PRNewswire] DEBIOPHARM REINFORCES THE BOND BETWEEN SWISS AND JAPANESE CANCER
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
"Japan and Switzerland share a variety of similar values such as commitment to excellence and professional diligence. With these values, we can maximize the chances that the next generation of drugs could result from collaboration between these two countries." expressed Thierry Mauvernay, President of Debiopharm. "Together with the JCA, Debiopharm hopes to encourage young scientists such as Drs Yoshimi and Sakata-Yanagimoto, to transfer their innovative research to the clinic and to the benefit of worldwide patients rapidly."
Since 2005, the Japanese Cancer Association (JCA) and Debiopharm have co-organized the 'JCA-Mauvernay Award'.
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
RESEARCH WITH THE 2022 JCA MAUVERNAY AWARD CEREMONY
-- Debiopharm awards the winning scientists for the JCA (Japanese Cancer Association) Award for innovative, disruptive, and translational oncology research
(LAUSANNE, Switzerland , Oct. 3, 2022 PRNewswire=연합뉴스) Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company, today announced the two winners of JCA Mauvernay Award for breakthrough Japanese oncology research projects in 2 categories: Innovative and/or Disruptive Research - Dr. Akihide Yoshimi and for Translational Research - Prof. Mamiko Sakata-Yanagimoto. The winners were honored with trophies and a monetary prize during the live event of the 81st Annual Meeting of the Japanese Cancer Association (JCA) on Saturday, October 1st in Yokohama, Japan by Prof. Hideyuki Saya President of the JCA and Thierry Mauvernay, President of Debiopharm, and Bertrand Ducrey CEO of Debiopharm.
"Japan and Switzerland share a variety of similar values such as commitment to excellence and professional diligence. With these values, we can maximize the chances that the next generation of drugs could result from collaboration between these two countries." expressed Thierry Mauvernay, President of Debiopharm. "Together with the JCA, Debiopharm hopes to encourage young scientists such as Drs Yoshimi and Sakata-Yanagimoto, to transfer their innovative research to the clinic and to the benefit of worldwide patients rapidly."
"The previous winners of the Mauvernay Award have immediately become very well-known scientists in our country, becoming professors and leaders in significant institutes. Therefore, I would say that the Mauvernay Award is definitely a huge step for young cancer research scientists in our country." stated Prof. Hideyuki Saya, President of the JCA.
Dr. Akihide Yoshimi's disruptive research at the National Cancer Center Research Institute, is aimed at understanding and targeting aberrant RNA splicing in hematological malignancies. He has contributed to the discovery of aberrant events in this process in tumor cells, identified key alterations in several splicing factors (SF) and provided insights into aberrant splicing and its association with key oncogenes (such as isocitrate dehydrogenase (IDH) and myelocytomatosis (Myc)). This work within an emerging field could have important biological as well as therapeutic implications for patient with SF mutant hematologic malignancies (e.g. in acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelomonocytic leukemia (CMML) and myelodysplastic syndrome (MDS)).
Prof. Mamiko Sakata-Yanagimoto's translational research at the Medicine Faculty of the University of Tsukuba is offering new insights into targeting intractable lymphomas with an elegant application of gene expression analysis in the aggressive angioimmunoblastic lymphoma (AITL). Her research started with the characterization of sequence of events between TET2 and RHOA mutations in the AITL patient samples (now included in the diagnostic criteria), continued with the identification of new actionable targets in the disease (RHOA/Vav1) and is currently focused on testing in the clinic therapeutic options using dasatinib to treat those patients.
The JCA-Mauvernay Award
Since 2005, the Japanese Cancer Association (JCA) and Debiopharm have co-organized the 'JCA-Mauvernay Award'. This prize illustrates the curiosity that drives researchers as well as the scientific cooperation between Japan and Switzerland. It aims to recognize the outstanding achievements in the field of oncology amongst Japanese researchers, in both the fundamental and the clinical aspects. The award has a total value of CHF 25'000.
Debiopharm's commitment to patients
Debiopharm develops innovative therapies that target high unmet medical needs in oncology and infectious diseases. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy and then select large pharmaceutical commercialization partners to maximize patient access globally.
For more information, please visit www.debiopharm.com
We are on Twitter. Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews
Debiopharm Contact
Dawn Haughton-Bonine
Communication Manager
dawn.bonine@debiopharm.com
Tel: +41 (0)21 321 01 11
Source: Debiopharm International SA
[편집자 주] 본고는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았음을 밝혀 드립니다.
(끝)
출처 : PRNewswire 보도자료
Copyright © 연합뉴스 보도자료. 무단전재 및 재배포 금지.
- "의대정원 증원 최대 절반까지 줄여 모집" 국립대 제안 해법될까(종합) | 연합뉴스
- 尹대통령-홍준표 만찬…洪 '김한길 총리·장제원 실장' 추천(종합2보) | 연합뉴스
- 이종섭측 "이첩 보고받고 직접 항명수사 지시"…윗선 개입 부정 | 연합뉴스
- 이화영측 "오후 5시 이후 술마셔"…출정일지엔 이미 구치소 복귀(종합) | 연합뉴스
- 총선 끝나자마자…치킨부터 초콜릿까지 먹거리 줄인상 | 연합뉴스
- 與, 참패 일주일째 혼돈…"위기 의식 없어" "할일 하는 중"(종합) | 연합뉴스
- 민주, '5월 국회' 입법 강공 드라이브…"할 수 있는 것 다한다" | 연합뉴스
- "국민연금은 기금이 아니라 국민위해 존재…소득대체율 높여야" | 연합뉴스
- IMF "韓, 반도체 등 수출 전망 긍정적…中 둔화가 리스크" | 연합뉴스
- 원/달러 환율, 한미일 공동 구두개입에 1,370원대로 급락 | 연합뉴스